Yasuhara H, Muto T
Department of Surgery, Faculty of Medicine, University of Tokyo, Japan.
Nihon Geka Gakkai Zasshi. 1998 Aug;99(8):510-7.
Reperfusion injury is recognized as a syndrome which impairs an ischemic organ as well as remote organs throughout the entire body. Previous research has revealed that the various inflammatory mediators, such as cytokines, platelet-activating factors, and free radicals, are involved and interact with each other in reperfusion injury. More recently, it has been demonstrated that neutrophils play an important role in the development of reperfusion injury. Thus the process of reperfusion injury is quite similar to that observed during the acute phase of inflammation. The same systemic reaction is also observed in multiple organ failure (MOF) or systemic inflammatory response syndrome (SIRS), where organ failure is a major determinant factor for the prognosis of patients. Regarding the treatment of organ failure due to reperfusion injury, several approaches using monoclonal antibody of adhesion molecules or receptor antagonist for cytokines have been introduced. Despite the current accumulation of knowledge, however, prevention is still the regimen for reperfusion injury and concomitant organ failure.
再灌注损伤被认为是一种损害缺血器官以及全身其他远端器官的综合征。先前的研究表明，各种炎症介质，如细胞因子、血小板活化因子和自由基，参与了再灌注损伤并相互作用。最近，已经证明中性粒细胞在再灌注损伤的发展中起重要作用。因此，再灌注损伤的过程与炎症急性期所观察到的过程非常相似。在多器官功能衰竭（MOF）或全身炎症反应综合征（SIRS）中也观察到相同的全身反应，其中器官功能衰竭是患者预后的主要决定因素。关于因再灌注损伤导致的器官功能衰竭的治疗，已经引入了几种使用粘附分子单克隆抗体或细胞因子受体拮抗剂的方法。然而，尽管目前已有大量知识积累，但预防仍然是再灌注损伤及伴随的器官功能衰竭的治疗方案。
